119 results on '"Qiu, Miaozhen"'
Search Results
2. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
3. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma
4. Unveiling prognosis and traits of dMMR/MSI-H gastric and colorectal cancer after curative surgery: A large-scale, multi-center, retrospective study in China.
5. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
6. Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms
7. Epstein-Barr virus infection associated with pepsinogens and Helicobacter pylori infection in patients with gastric cancer
8. A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1
9. Abstract 6140: Caspase-3 mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
10. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.
11. An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
12. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
13. Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer
14. Phase II Study of SOXIRI (S-1/Oxaliplatin/Irinotecan) Chemotherapy in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Prospective Study (Preprint)
15. Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systematic therapy of gastric cancer.
16. Editorial: The Role of Sex Dimorphism in Disease Susceptibility and Immune Response
17. Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy
18. Prediabetes and the risk of cancer: a meta-analysis
19. PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: A prospective single-arm, open-label, phase 2 trial.
20. Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.
21. A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer.
22. A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01).
23. Prognostic effect of high pretreatment neutrophil to lymphocyte ratio on survival of patients with gastric adenocarcinoma in China
24. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms
25. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
26. Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis
27. Determination of follistatin-like protein 1 expression in colorectal cancer and its association with clinical outcomes
28. Abstract 2054: A novel Bcl-2/Bcl-XL inhibitor APG-1252-12A as a potential therapeutic strategy for gastric carcinoma
29. Abstract 309: FAK blockade enhances antitumor effect of BTK inhibitor in esophageal squamous cell carcinoma via EGFR-ERK-Akt pathway inhibition
30. Abstract 3958: FAK inhibition reduces tumor infiltration of Tregs via restricting CCL5 release and boosts the present therapeutic regimen for BRAFV600E-mutated colorectal carcinoma
31. Abstract 2061: A novel small molecule inhibitor of MDM2-p53 (APG-115) has antitumor activity in gastric adenocarcinoma
32. Lymph node ratio as a valuable prognostic factor for patients with colorectal liver-only metastasis undergoing curative resection
33. Abstract 301: Targeting the anti-apoptotic BCL-2 family protein provides an effective and precise therapeutic strategy for NHL
34. Incidence rate and clinic-pathologic features of EBV-associated gastric carcinoma in China.
35. A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
36. Does the Preoperative Prognostic Nutritional Index Predict Survival in Patients with Liver Metastases from Colorectal Cancer Who Underwent Curative Resection?
37. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery
38. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells
39. Incidence rate and clinical-pathological features of hereditary diffuse gastric cancer patients in China.
40. Association between lymph node examination and nodal staging for pancreatic adenocarcinoma: A population-based analysis.
41. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells
42. Evaluation of MET and HER2 expression in primary and metastatic tumor in Chinese advanced gastric cancer patients.
43. Impact of marital status on survival of gastric adenocarcinoma patients: Results from the Surveillance Epidemiology and End Results (SEER) Database
44. The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer (ESCC)
45. Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value
46. Mobilizing social support networks to improve cancer screening: the COACH randomized controlled trial study design
47. Pattern of distant metastases in colorectal cancer: a SEER based study
48. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study
49. Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: Results from the surveillance epidemiology and end results (SEER) database
50. Evaluation of tumor MET protein expression, MET gene amplification, and HER2 expression in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.